{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_1839"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_1839","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Evaluation of therapeutic response of histiocytic sarcoma cell lines to novel small molecule inhibitors of receptor tyrosine kinases","abstract":"The current standard of care treatment for canine histiocytic sarcoma (HS) is based on the administration of conventional chemotherapeutic drugs, which results in low percentage of partial and short-term favorable responses. In order to identify novel drug candidates for the treatment of dogs with HS, we investigated the cytostatic activity of a panel of sixteen compounds over two canine HS cell lines. Our results demonstrated that dasatinib, a receptor tyrosine kinase pan-inhibitor, and other novel molecularly-targeted drugs JQ1, a BET bromodomain inhibitor, and bortezomib, a proteasome inhibitor, effectively inhibited the growth of HS cells in vitro. The antiproliferative response of dasatinib was augmented when combined to doxorubicin, a classical chemotherapeutic agent. For all these drugs, the effective inhibitory concentration in vitro was within a clinically achievable and tolerable plasma concentration in vivo, as described in the veterinary and human medicine literature. In this study we identified three molecularly targeted drugs that may represent a promising anticancer strategy for canine HS. Further in vivo studies and clinical trials are needed to fully evaluate therapeutic potential of these drugs in HS in dogs and in similar disorders in humans.","abstract_html":"The current standard of care treatment for canine histiocytic sarcoma (HS) is based on the administration of conventional chemotherapeutic drugs, which results in low percentage of partial and short-term favorable responses. In order to identify novel drug candidates for the treatment of dogs with HS, we investigated the cytostatic activity of a panel of sixteen compounds over two canine HS cell lines. Our results demonstrated that dasatinib, a receptor tyrosine kinase pan-inhibitor, and other novel molecularly-targeted drugs JQ1, a BET bromodomain inhibitor, and bortezomib, a proteasome inhibitor, effectively inhibited the growth of HS cells in vitro. The antiproliferative response of dasatinib was augmented when combined to doxorubicin, a classical chemotherapeutic agent. For all these drugs, the effective inhibitory concentration in vitro was within a clinically achievable and tolerable plasma concentration in vivo, as described in the veterinary and human medicine literature. In this study we identified three molecularly targeted drugs that may represent a promising anticancer strategy for canine HS. Further in vivo studies and clinical trials are needed to fully evaluate therapeutic potential of these drugs in HS in dogs and in similar disorders in humans.","abstract_has_math":false,"creators":["Takada, Marilia"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Yuzbasiyan-Gurkan, Vilma","Kiupel, Matti","Dervisis, Nikolaos","Hauptman, Joseph"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-11-18T17:42:38Z","subjects":["Cancer in animals","Dogs--Diseases","Protein-tyrosine kinase","Reticulum cell sarcoma","Veterinary oncology"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:1839","isbn:9781303334061","isbn:1303334062","oclc:931742379","umi:1544076","local:Takada_grad.msu_0128N_12334"],"render_values":[{"text":"etd:1839","href":null,"code":true},{"text":"isbn:9781303334061","href":null,"code":true},{"text":"isbn:1303334062","href":null,"code":true},{"text":"oclc:931742379","href":null,"code":true},{"text":"umi:1544076","href":null,"code":true},{"text":"local:Takada_grad.msu_0128N_12334","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/jec9-qc04","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/jec9-qc04","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_1839","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Yuzbasiyan-Gurkan, Vilma","Kiupel, Matti","Dervisis, Nikolaos","Hauptman, Joseph"]},{"key":"dc:creator","label":"Author","values":["Takada, Marilia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cancer in animals","Dogs--Diseases","Protein-tyrosine kinase","Reticulum cell sarcoma","Veterinary oncology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:1839","isbn:9781303334061","isbn:1303334062","oclc:931742379","umi:1544076","local:Takada_grad.msu_0128N_12334","https://doi.org/doi:10.25335/jec9-qc04"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The current standard of care treatment for canine histiocytic sarcoma (HS) is based on the administration of conventional chemotherapeutic drugs, which results in low percentage of partial and short-term favorable responses. In order to identify novel drug candidates for the treatment of dogs with HS, we investigated the cytostatic activity of a panel of sixteen compounds over two canine HS cell lines. Our results demonstrated that dasatinib, a receptor tyrosine kinase pan-inhibitor, and other novel molecularly-targeted drugs JQ1, a BET bromodomain inhibitor, and bortezomib, a proteasome inhibitor, effectively inhibited the growth of HS cells in vitro. The antiproliferative response of dasatinib was augmented when combined to doxorubicin, a classical chemotherapeutic agent. For all these drugs, the effective inhibitory concentration in vitro was within a clinically achievable and tolerable plasma concentration in vivo, as described in the veterinary and human medicine literature. In this study we identified three molecularly targeted drugs that may represent a promising anticancer strategy for canine HS. Further in vivo studies and clinical trials are needed to fully evaluate therapeutic potential of these drugs in HS in dogs and in similar disorders in humans.","Thesis (M.S.)--Michigan State University. Small Animal Clinical Sciences, 2013","Includes bibliographical references (pages 48-59)"]},{"key":"dc:format","label":"Dc Format","values":["x, 59 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Evaluation of therapeutic response of histiocytic sarcoma cell lines to novel small molecule inhibitors of receptor tyrosine kinases"]}]}],"canonical_facts":{"dc:contributor":["Yuzbasiyan-Gurkan, Vilma","Kiupel, Matti","Dervisis, Nikolaos","Hauptman, Joseph"],"dc:creator":["Takada, Marilia"],"dc:date":["2013"],"dc:description":["The current standard of care treatment for canine histiocytic sarcoma (HS) is based on the administration of conventional chemotherapeutic drugs, which results in low percentage of partial and short-term favorable responses. In order to identify novel drug candidates for the treatment of dogs with HS, we investigated the cytostatic activity of a panel of sixteen compounds over two canine HS cell lines. Our results demonstrated that dasatinib, a receptor tyrosine kinase pan-inhibitor, and other novel molecularly-targeted drugs JQ1, a BET bromodomain inhibitor, and bortezomib, a proteasome inhibitor, effectively inhibited the growth of HS cells in vitro. The antiproliferative response of dasatinib was augmented when combined to doxorubicin, a classical chemotherapeutic agent. For all these drugs, the effective inhibitory concentration in vitro was within a clinically achievable and tolerable plasma concentration in vivo, as described in the veterinary and human medicine literature. In this study we identified three molecularly targeted drugs that may represent a promising anticancer strategy for canine HS. Further in vivo studies and clinical trials are needed to fully evaluate therapeutic potential of these drugs in HS in dogs and in similar disorders in humans.","Thesis (M.S.)--Michigan State University. Small Animal Clinical Sciences, 2013","Includes bibliographical references (pages 48-59)"],"dc:format":["x, 59 pages","application/pdf"],"dc:identifier":["etd:1839","isbn:9781303334061","isbn:1303334062","oclc:931742379","umi:1544076","local:Takada_grad.msu_0128N_12334","https://doi.org/doi:10.25335/jec9-qc04"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Cancer in animals","Dogs--Diseases","Protein-tyrosine kinase","Reticulum cell sarcoma","Veterinary oncology"],"dc:title":["Evaluation of therapeutic response of histiocytic sarcoma cell lines to novel small molecule inhibitors of receptor tyrosine kinases"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T17:42:38Z"}